Top

Published in:

01-12-2016 | Neurology and Preclinical Neurological Studies - Short communication

Weight loss and decubitus duodenal ulcer in Parkinson’s disease treated with levodopa–carbidopa intestinal gel infusion

Authors: Tommaso Martino, Donato Melchionda, Paolo Tonti, Vincenzo De Francesco, Alessandra Lalla, Luigi Maria Specchio, Carlo Avolio

Published in: Journal of Neural Transmission | Issue 12/2016

Abstract

Apparently, unexplained weight loss is a common symptom experienced by patients affected by Parkinson’s disease, especially in those treated by levodopa–carbidopa infusion gel (LCIG) with a poor control of dyskinesias. Weight loss is considered part of gastrointestinal dysfunction seen in patients affected by Parkinson’s disease, along with gastroparesis and reduced bowel peristalsis. In patients treated with LCIG, weight loss needs to be accurately evaluated, because of possible underlying life-threatening adverse events, like duodenum decubitus ulcer.

Abbott RA, Cox M, Markus H, Tomkins A (1992) Diet, body size and micronutrient status in Parkinson’s disease. Eur J Clin Nutr 46(12):879–884PubMed

Antonini A, Odin P, Tomantschger V, Pacchetti C, Pickut B, Gasser UE et al (2013) Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm 120(11):1553–1558CrossRefPubMed

Antonini A, Yegin A, Preda C, Bergmann L, Poewe W (2015) Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat D 21(3):231–235CrossRef

Braak H, de Vos RA, Bohl J, Del Tredici K (2006) Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 396(1):67–72CrossRefPubMed

Buongiorno M, Antonelli F, Cámara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J et al (2015) Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat D 21(8):871–876CrossRef

Calandrella D, Romito LM, Elia AE, Del Sorbo F, Bagella CF, Falsitta M, Albanese A (2015) Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. Neurology 84(16):1669–1672CrossRefPubMed

Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF (2015) Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 14(6):625–639CrossRefPubMed

Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F et al (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Movement Disord 30(4):500–509CrossRefPubMed

Olivares A, Collado D, Muñoz-Navas M, Calvo M, Olivo E, Chico I et al (2012) Complications of percutaneous endoscopic gastrostomy-jejunostomy for levodopa/carbidopa infusion in advanced Parkinson’s disease. Gastroenterol Insights 4:e4CrossRef

Pålhagen SE, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J et al (2012) Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 126(6):e29–e33CrossRefPubMed

Papapetropoulos S, Mash DC (2007) Motor fluctuations and dyskinesias in advanced/end stage Parkinson’s disease: a study from a population of brain donors. J Neural Transm 114(3):341–345CrossRefPubMed

Pfeiffer RF (2011) Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism Relat D 17(1):10–15CrossRef

Schrag A, Horsfall L, Walters K, Noyce A, Petersen I (2015) Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 14(1):57–64CrossRefPubMed

Sensi M, Preda F, Trevisani L, Contini E, Gragnaniello D, Capone JG et al (2014) Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients. J Neural Transm 121(6):633–642CrossRefPubMed

Visanji NP, Marras C, Hazrati LN, Liu LW, Lang AE (2014) Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson’s disease biomarker. Movement Disord 29(4):444–450CrossRefPubMed

Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D et al (2014) Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. Eur J Neurol 21(2):312–318CrossRefPubMed

Title: Weight loss and decubitus duodenal ulcer in Parkinson’s disease treated with levodopa–carbidopa intestinal gel infusion
Authors: Tommaso Martino
Donato Melchionda
Paolo Tonti
Vincenzo De Francesco
Alessandra Lalla
Luigi Maria Specchio
Carlo Avolio
Publication date: 01-12-2016
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 12/2016
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-016-1618-2

At a glance: The STEP trials

Springer Medicine

Weight loss and decubitus duodenal ulcer in Parkinson’s disease treated with levodopa–carbidopa intestinal gel infusion

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2016

Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson’s disease

Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer’s disease and in mild cognitive impairment due to AD

Abstracts of the Third International Congress on Treatment of Dystonia, 4–7 May 2016, Hannover, Germany

Neuroprotective effects of various doses of topiramate against methylphenidate-induced oxidative stress and inflammation in isolated rat amygdala: the possible role of CREB/BDNF signaling pathway

Theta burst stimulation over premotor cortex in Parkinson’s disease: an explorative study on manual dexterity

Repetitive transcranial magnetic stimulation (rTMS) combined with cognitive training is a safe and effective modality for the treatment of Alzheimer’s disease: clinical experience